Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries
- Ostenson, Claes-Göran
- Matthaei, Stephan
- Reaney, Matthew
- Krarup, Thure
- Guerci, Bruno
- Kiljanski, Jacek
- Salaun-Martin, Carole
- Sapin, Hélène
- Bruhn, David
- Mathieu, Chantal
- Theodorakis, Michael
Publication date
January 2013
DOI Publisher
Dove Medical Press Ltd. ISSN
1178-7007 Journal
1178-7007Abstract
The CHanges to treatment and Outcomes in patients with type 2 diabetes initiating InjeCtablE therapy (CHOICE) study assessed time to, and reasons for, significant treatment change after patients with type 2 diabetes (T2DM) initiated their first injectable glucose-lowering therapy (exenatide twice daily [BID] or insulin) in routine clinical practice, and these patients' clinical outcomes, in six European countries. This paper reports interim data from the first 12 months of the study.status: publishe
Add to ORKG